NCT07716241尚未招募1 期
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Administration of HS-20136-2 Injection in Healthy/Obese Participants
Jiangsu Hansoh Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 92 人开始时间: 2026年9月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- Number of Adverse Events
研究概览
简要总结
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HS-20136-2 injection in healthy/obese participants.
详细描述
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Administration of HS-20136-2 Injection in Healthy/Obese Participants
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged between 18 and 55 years (inclusive) at screening, male or female.
- •Participants must fully understand the study content, procedures, and potential adverse reactions, and voluntarily sign the informed consent form (ICF) prior to any study-related procedures.
- •Agree to use effective contraceptive measures and refrain from sperm or egg donation from the time of signing the ICF until 4 months after the last dose.
- •Agree to abstain from alcohol, smoking, and food or beverages containing xanthine or caffeine (including chocolate, tea, coffee, cola, etc.), and refrain from strenuous exercise from 48 hours prior to dosing until discharge from the study site.
- •Self-reported body weight fluctuation of ≤ 5.0% within 12 weeks prior to screening through diet and exercise control alone.
- •Willing and able to maintain a stable diet and exercise lifestyle throughout the study period.
- •SAD cohort: body weight ≥ 50 kg, BMI 19.0-28.0 kg/m² (inclusive). MAD cohort: BMI 28.0-40.0 kg/m² (inclusive).
排除标准
- •History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, psychiatric, neurological, hematological, immunological, or metabolic disorders (e.g., recurrent hypoglycemia of unknown cause) that, in the investigator's opinion, would make the participant unsuitable for participation in this study.
- •Clinically significant abnormalities in vital signs, physical examination, laboratory tests, or 12-lead electrocardiogram (ECG) at screening, as judged by the investigator.
- •Presence of diseases that, in the investigator's judgment, may significantly affect drug or nutrient absorption, including clinically significant gastrointestinal disorders (e.g., active inflammatory bowel disease) or symptoms of gastrointestinal disturbance; or any condition that may affect drug absorption, such as subtotal or total gastrectomy, sleeve gastrectomy, gastric bypass surgery, or resection of any intestinal segment.
- •Diagnosis of chronic pancreatitis or history of idiopathic acute pancreatitis, or serum amylase or lipase above the upper limit of normal (ULN) at screening. Participants with a history of acute pancreatitis due to cholelithiasis may be enrolled if they have undergone cholecystectomy.
- •History of acute cholecystitis, or presence of symptomatic/stone-related cholelithiasis requiring treatment on prior or screening ultrasound (except for participants who have undergone cholecystectomy and are deemed eligible by the investigator).
- •Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2), or screening calcitonin level ≥ 50 ng/L.
- •Participation in any other clinical trial of a drug or medical device within 3 months prior to screening (excluding those who did not receive the investigational product or device).
- •History of diabetes mellitus (type 1, type 2, or rare forms of diabetes).
- •Presence of endocrine disorders or history thereof that may significantly affect body weight (e.g., Cushing's syndrome, hypothyroidism, or hyperthyroidism; except for hypothyroidism managed with a stable thyroid hormone replacement regimen for at least 6 months), or obesity due to single-gene mutations or hereditary obesity syndromes.
- •Use of any medication or treatment known to cause significant weight gain or weight loss within 3 months prior to screening.
- •Any other condition that, in the investigator's opinion, would make the participant unsuitable for enrollment in this study.
结局指标
主要结局
Number of Adverse Events
时间窗: Start of Treatment to end of study (approximately 57 days or 112 days)
A summary of adverse events, including Serious Adverse Events(SAEs)
次要结局
- Area under the plasma concentration-time curve (AUC) of HS-20136-2(Start of Treatment to end of study (approximately 57 days))
- AUC of HS-20136-2(Start of Treatment to end of study (approximately 112 days))
- Immunogenicity(Start of Treatment to end of study (approximately 112 days))
- body weight change(Start of Treatment to end of study (approximately 112 days))
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Clinical Study of HRS-8797 in Healthy ParticipantsAtopic DermatitisNCT07698756Chengdu Suncadia Medicine Co., Ltd.74
招募中
1 期
Phase I Study of HXN6005 in Adult Healthy ParticipantsNCT07449741Helixon Biotechnology (Suzhou) Co., Ltd32
已完成
1 期
A Study of HS-10518 in Healthy Adult Premenopausal Females in ChinaNCT07264192West China Second University Hospital60
招募中
2 期
A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone BlockadeNCT07459166Clear Scientific, Inc.16
已完成
1 期
A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients .NCT07618351Peking University First Hospital627